Anatomical Breast Imaging Derived Parameters Do Not Provide Incremental Information In Prediction of Nonvisualization of Sentinel Lymph Nodes On Lymphoscintigraphy

Abstract Background: Accurate sentinel lymph node (SLN) staging is essential for both prognosis and treatment in patients with breast cancer. However, the preoperative lymphoscintigraphy may fail to visualize the SLN. The aim of this retrospective study was to investigate whether parameters derived from anatomical breast imaging can predict SLN nonvisualization on lymphoscintigraphy. For this single-center retrospective study all data of mammography, breast magnetic resonance imaging (MRI), and lymphoscintigraphy of SLN procedures from January 2016 to April 2021 were collected and reviewed from the Amsterdam UMC electronic health records database.Results: A total of 758 breast cancer patients were included in this study. The SLN nonvisualization rate was 29.7% on lymphoscintigraphy. Multivariable analysis showed that age ≥ 70 years (P = 0.019; OR: 1.82; 95% CI: 1.10–3.01), BMI ≥ 30 kg/m2 (P = 0.031; OR: 1.59; 95% CI: 1.04–2.43), and nonpalpable tumors (P = 0.034; OR: 1.54; 95% CI: 1.03–2.04) were independent predictors of SLN nonvisualization. Differences in tumor size, Breast Imaging-Reporting and Data System (BI-RADS) classification, or breast density were not significantly associated with SLN nonvisualization.Conclusions: This study shows that, by using a multivariable analysis, risk factors for SLN nonvisualization in breast cancer patients during preoperative lymphoscintigraphy are age ≥70 years, BMI ≥30 kg/m2, and nonpalpable tumors. Parameters derived from mammography or breast MRI, however, are not useful to predict SLN nonvisualization on lymphoscintigraphy.

Download Full-text

Risk factors for nonvisualization of the sentinel lymph node on lymphoscintigraphy in breast cancer patients

EJNMMI Research ◽

10.1186/s13550-021-00793-8 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Youssef Chahid ◽

Xinbo Qiu ◽

Ewoudt M. W. van de Garde ◽

Hein J. Verberne ◽

Jan Booij

Keyword(s):

Breast Cancer ◽

Risk Factors ◽

Lymph Node ◽

Retrospective Study ◽

Sentinel Lymph Node ◽

Cancer Patients ◽

Multivariable Analysis ◽

Tumor Location ◽

Breast Cancer Patients ◽

Factors Associated

Abstract Background Accurate sentinel lymph node (SLN) staging is essential for both prognosis and treatment in patients with breast cancer. However, the preoperative lymphoscintigraphy may fail to visualize the SLN in some patients. The purpose of this retrospective study was to identify risk factors associated with SLN nonvisualization on lymphoscintigraphy. For this single-center retrospective study, all data of lymphoscintigraphy of SLN procedures from March 2011 to April 2021 were collected and reviewed from the Amsterdam UMC database. Results A total of 1886 SLN procedures were included in this study. The SLN nonvisualization rate was 25.1% on lymphoscintigraphy at 4 h post-injection. The SLN nonvisualization rate decreased to 9.4% after reinjection. Multivariable analysis showed that age ≥ 70 years (P < 0.001; OR: 2.27; 95% CI: 1.46–3.53), BMI ≥ 30 kg/m2 (P = 0.031; OR: 1.48; 95% CI: 1.04–2.12) and nonpalpable tumors (P = 0.004; OR: 1.54; 95% CI: 1.15–2.07) were independent predictors of SLN nonvisualization. Tumor location, brand of radiopharmaceutical, injected dose and volume, experience of preparer and administrator were not associated with SLN nonvisualization. None of the patient, tumor or tracer characteristics were associated with SLN nonvisualization after radiotracer reinjection. Conclusions This study shows that risk factors for SLN nonvisualization in breast cancer patients during preoperative lymphoscintigraphy are age ≥ 70 years, BMI ≥ 30 kg/m2 and nonpalpable tumors. Our results support the notion that SLN lymphoscintigraphy is a very robust technique that does not depend on the experience of the preparer or administrator of the radiotracer.

Download Full-text

Preoperative axillary lymph node evaluation in breast cancer patients by breast magnetic resonance imaging (MRI): Can breast MRI exclude advanced nodal disease?

European Radiology ◽

10.1007/s00330-016-4235-4 ◽

2016 ◽

Vol 26 (11) ◽

pp. 3865-3873 ◽

Cited By ~ 30

Author(s):

Su Jeong Hyun ◽

Eun-Kyung Kim ◽

Hee Jung Moon ◽

Jung Hyun Yoon ◽

Min Jung Kim

Keyword(s):

Breast Cancer ◽

Breast Magnetic Resonance Imaging ◽

Breast Mri ◽

Axillary Lymph ◽

Breast Cancer Patients ◽

Resonance Imaging ◽

Nodal Disease ◽

Breast Magnetic Resonance ◽

Magnetic Resonance Imaging Mri ◽

Lymph Node Evaluation

Download Full-text

The Tumor–Fat Interface Volume of Breast Cancer on Pretreatment MRI Is Associated with a Pathologic Response to Neoadjuvant Chemotherapy

Biology ◽

10.3390/biology9110391 ◽

2020 ◽

Vol 9 (11) ◽

pp. 391

Author(s):

Hwan-ho Cho ◽

Minsu Park ◽

Hyunjin Park ◽

Eun Sook Ko ◽

Na Young Hwang ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Cancer Patients ◽

Quantitative Measurement ◽

Pathologic Complete Response ◽

Complete Response ◽

Breast Cancer Patients ◽

Breast Magnetic Resonance ◽

Magnetic Resonance Imaging Mri ◽

Development And Validation

Adipocytes are active sources of numerous adipokines that work in both a paracrine and endocrine manner. It is not known that the direct contact between tumor and neighboring fat measured by pretreatment breast magnetic resonance imaging (MRI) affects treatment outcomes to neoadjuvant chemotherapy (NAC) in breast cancer patients. A biomarker quantifying the tumor–fat interface volume from pretreatment MRI was proposed and used to predict pathologic complete response (pCR) in breast cancer patients treated with NAC. The tumor–fat interface volume was computed with data-driven clustering using multiphasic MRI. Our approach was developed and validated in two cohorts consisting of 1140 patients. A high tumor–fat interface volume was significantly associated with a non-pCR in both the development and validation cohorts (p = 0.030 and p = 0.037, respectively). Quantitative measurement of the tumor–fat interface volume based on pretreatment MRI may be useful for precision medicine and subsequently influence the treatment strategy of patients.

Download Full-text

Risk factors for nonvisualization of the sentinel lymph node on lymphoscintigraphy in breast cancer patients

10.21203/rs.3.rs-443895/v1 ◽

2021 ◽

Author(s):

Youssef Chahid ◽

Xinbo Qiu ◽

Ewoudt M.W. van de Garde ◽

Hein J. Verberne ◽

Jan Booij

Keyword(s):

Breast Cancer ◽

Risk Factors ◽

Lymph Node ◽

Retrospective Study ◽

Sentinel Lymph Node ◽

Cancer Patients ◽

Multivariable Analysis ◽

Tumor Location ◽

Breast Cancer Patients ◽

Factors Associated

Abstract BackgroundAccurate sentinel lymph node (SLN) staging is essential for both prognosis and treatment in patients with breast cancer. However, the preoperative lymphoscintigraphy may fail to visualize the SLN in some patients. The purpose of this retrospective study was to identify risk factors associated with SLN nonvisualization on lymphoscintigraphy. For this single-center retrospective study all data of lymphoscintigraphy of SLN procedures from March 2011 to April 2021 were collected and reviewed from the Amsterdam UMC database. ResultsA total of 1886 SLN procedures were included in this study. The SLN nonvisualization rate was 25.1% on lymphoscintigraphy at 4 hours post injection. The SLN nonvisualization rate decreased to 9.4% after reinjection. Multivariable analysis showed that age ≥70 years (P<0.001; OR: 2.27; 95% CI: 1.46–3.53), BMI ≥30 kg/m2 (P=0.031; OR: 1.48; 95% CI: 1.04–2.12), and nonpalpable tumors (P=0.004; OR: 1.54; 95% CI: 1.15–2.07) were independent predictors of SLN nonvisualization. Tumor location, brand of radiopharmaceutical, injected dose and volume, experience of preparer and administrator were not associated with SLN nonvisualization. None of the patient, tumor or tracer characteristics were associated with SLN nonvisualization after radiotracer reinjection.ConclusionsThis study shows that risk factors for SLN nonvisualization in breast cancer patients during preoperative lymphoscintigraphy are age ≥70 years, BMI ≥30 kg/m2, and nonpalpable tumors. Our results support the notion that SLN lymphoscintigraphy is a very robust technique, that does not depend on the experience of the preparer or administrator of the radiotracer.

Download Full-text

63O A nation-wide multicenter 10-Year (1999-2008) retrospective study of chemotherapy in Chinese breast cancer patients

Annals of Oncology ◽

10.1016/s0923-7534(21)00223-4 ◽

2016 ◽

Vol 27 ◽

pp. ix19

Author(s):

Q. Li ◽

P. Zhang ◽

Z. Yang ◽

J. Fan ◽

J. He ◽

...

Keyword(s):

Breast Cancer ◽

Retrospective Study ◽

Cancer Patients ◽

Breast Cancer Patients

Download Full-text

Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting

Journal of Cancer Epidemiology ◽

10.1155/2012/941495 ◽

2012 ◽

Vol 2012 ◽

pp. 1-6 ◽

Cited By ~ 9

Author(s):

Teri L. Malo ◽

Isaac Lipkus ◽

Tobi Wilson ◽

Hyo S. Han ◽

Geza Acs ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Cancer Patients ◽

Multivariable Analysis ◽

Recurrence Score ◽

Treatment Decision ◽

Breast Cancer Patients ◽

Multivariable Logistic Regression Model ◽

Treatment Decision Making ◽

Inform Treatment Decision

Introduction. This study aimed to evaluate whether OncotypeDx test results predict receipt of adjuvant chemotherapy in breast cancer patients who received an OncotypeDx recurrence score (RS).Materials and Methods. Pathology records were used to identify breast cancer patients who had OncotypeDx testing between December 2004 and January 2009 (n=118). Patient sociodemographic information, tumor characteristics, RS, and treatment-specific data were collected via chart review. RS was classified as follows: low (RS≤17), intermediate (RS = 18–30), or high (RS≥31). Bivariate analyses were conducted to investigate the relationship between adjuvant chemotherapy receipt and each sociodemographic and clinical characteristic; significant sociodemographic and clinical variables were included in a multivariable logistic regression model.Results. In multivariable analysis controlling for tumor size, histologic grade, and nuclear grade, only RS remained significantly associated with chemotherapy uptake. Relative to low RS, an intermediate (adjusted odds ratio [AOR], 21.24; 95% confidence interval [CI], 3.62–237.52) or high (AOR, 15.07; 95% CI, 1.28–288.21) RS was associated with a greater odds of chemotherapy uptake.Discussion. Results indicate that RS was significantly associated with adjuvant chemotherapy uptake, suggesting that OncotypeDx results were used to inform treatment decision making, although it is unclear if and how the information was conveyed to patients.

Download Full-text